www.stemcellmedicine.tv
| 2 months ago
... of a gene therapy treatment for disease in the West. The European Medicine Agency's Committee for Medicinal Products for Human Use said Friday that it is recommending approval of Glybera, a treatment for lipoprotein lipase deficiency ...
www.fiercepharma.com
| 2 months ago
It took four attempts, but UniQure's Glybera has been recommended for approval by the European Medicines Agency as the first gene therapy treatment in a Western nation. It is for treatment of the rare condition lipoprotein lipase deficiency, ...
europe-health-care.eu
| 2 months ago
UniQure's gene therapy for lipoprotein lipase deficiency recommended for approval as Orphan Drug. uniQure announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a ...
www.stemcellmedicine.tv
| 2 months ago
uniQure has developed Glybera as a therapy for patients with the genetic disorder lipoprotein lipase deficiency. LPLD is an orphan disease for which no treatment exists today. The disease is caused by mutations in the LPL gene, resulting in ...
community.parentprojectmd.org
| 2 months ago
This would be the first regulatory approval for a gene therapy in the Western world. It treats lipoprotein lipase deficiency, a rare genetic disorder. Interesting article... http://www.nytimes.com/2012/07/21/health/european-agency-recommends.